Mecbotamab vedotin (BA3011) is a conditionally active anti-AXL and MMAE ADC currently under clinical investigation in a phase 1/2 study of mecbotamab vedotin alone or in combination with nivolumab in adult and adolescent patients with advanced refractory sarcoma (NCT03425279) (49, 50). This evidence concerns the gene AXL and sarcoma.